ONCONANOBBB

Development and evaluation of a quantitative imaging technique for assessment of nanoparticle drug delivery across the blood-brain barrier: Applications for brain cancer therapeutics

Coordinatore	TECHNOLOGIKO EKPAIDEFTIKO IDRYMA ATHINAS    more  Organization address address: AGIOU SPYRIDONOS 28 KAI MILOU 1 city: AIGALEO postcode: 12210 contact info Titolo: Ms. Nome: Ifigeneia Cognome: Anastasakou Email: send email Telefono: 302105000000 Fax: 302105000000
Nazionalità Coordinatore	Greece [EL]
Totale costo	849˙958 €
EC contributo	849˙958 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2011-IAPP
Funding Scheme	MC-IAPP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-01-01   -   2015-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	TECHNOLOGIKO EKPAIDEFTIKO IDRYMA ATHINAS  Organization address address: AGIOU SPYRIDONOS 28 KAI MILOU 1 city: AIGALEO postcode: 12210 contact info Titolo: Ms. Nome: Ifigeneia Cognome: Anastasakou Email: send email Telefono: 302105000000 Fax: 302105000000	EL (AIGALEO)	coordinator	256˙574.00
2	Pharmidex Pharmaceutical Services Limited  Organization address address: HANOVER STREET 14 FLOOR 3 city: LONDON postcode: W1S 1RR contact info Titolo: Dr. Nome: Mo Cognome: Alavijeh Email: send email Telefono: 448702000000 Fax: 448451000000	UK (LONDON)	participant	487˙803.00
3	UNIVERSITY OF BRIGHTON  Organization address address: "Lewes Road, Mithras House" city: BRIGHTON postcode: BN2 4AT contact info Titolo: Prof. Nome: Sergey Cognome: Mikhalovsky Email: send email Telefono: +44 1273 642115	UK (BRIGHTON)	participant	105˙581.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The partners wish to build a long term European, Industry-Academia consortium, to work on the problem of delivering therapeutic agents, e.g. for brain cancer, across the blood-brain barrier (BBB) at the efficacious dose. Current treatment options for brain cancer are limited with patients having a poor prognosis. One of the major hurdles is the BBB which prevents effective doses of drugs reaching the site of disease. There is thus a major need for technologies that can successfully overcome such a hurdle without having a negative effect on safety and tolerability. Pharmidex have developed a drug delivery system that transiently and reversibly opens the BBB to entry of compounds into the brain without inducing tissue injury. It is based on patented lipid-like structures and has been shown to deliver both small molecules and large proteins effectively into the brain. The lead delivery compound for brain cancer appears to be safe and well tolerated on the basis of pre-clinical testing. We initially seek to determine the mechanism of action of the technology for penetrating the BBB; application to different therapeutic agents as well as development of reliable brain cancer animal models to quantify efficacy of nanoparticle-based therapy using imaging technology. We believe this novel delivery technology will be a unique drug discovery tool with the potential to enhance efficacy of established agents, reduce systemic exposure of the chemotherapeutic agent, thus minimising both the on/off-target toxicity through enhancement of drug absorption at the target site. Besides its scientific objectives, OncoNanoBBB will provide a framework for cooperation and knowledge sharing between a pharmaceutical industry and two academic institutions with complementary expertise in project objectives, as well as dissemination of project outcomes.'

Introduzione (Teaser)

Inefficient delivery of the therapeutic agents across the blood-brain barrier (BBB) results in poor prognosis for brain cancer patients. An EU consortium is developing imaging methods for assessing non-invasively brain delivery systems.